Financial Performance - Net sales decreased by 50% year-over-year, reaching $904 million in Q3 2025 compared to $951 million in Q3 2024[9] - Constant currency net sales decreased by 80%, including a 55% impact from Q3 2024 Byte impact and ERP pre-buy[14, 16] - Adjusted EBITDA margin increased by 50 bps year-over-year to 184%[9, 11, 16] - Adjusted EPS decreased by 265% year-over-year to $037[9, 12, 16] - Operating cash flow was $79 million[9, 13] Segment Results - Connected Technology Solutions (CTS) sales decreased by 39% as reported and 70% in constant currency[17] - Essential Dental Solutions (EDS) sales decreased by 34% as reported and 62% in constant currency, primarily due to a $24 million Q3 2024 pre-buy[17] - Orthodontic and Implant Solutions (OIS) sales decreased by 150% as reported and 171% in constant currency, impacted by a ~$30 million Byte year-over-year impact[17] - Wellspect Healthcare sales increased by 156% as reported and 93% in constant currency[17] Geographic Performance - U S net sales decreased by 222% in constant currency, including a 125% impact from Q3 2024 Byte impact and ERP pre-buy, reaching $291 million[16] - Europe net sales increased by 26% in constant currency, reaching $382 million[16] - Rest of World net sales decreased by 09% in constant currency, reaching $231 million[16] Revised Outlook - The company revised its 2025 constant currency outlook to a decline of 5% to 4%[19] - The company maintains its reported sales outlook at $36 billion - $37 billion[19] - The company revised its adjusted EBITDA margin outlook to >18%[19] - The company revised its adjusted EPS outlook to ~$160[19]